Objective Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19
infections, and cytokine storm is associated with disease severity. Tocilizumab, an …

Introduction A novel coronavirus pneumonia (COVID-19) has caused significant life loss and
healthcare burden globally. COVID-19 is known to cause a cytokine release syndrome …

Objectives: To determine the impact of tocilizumab, a monoclonal antibody against the
interleukin 6 receptor, on survival in patients with coronavirus disease 2019. Design …

Simple Summary The world has been stricken mentally, physically, and economically by the
COVID-19 virus. However, while SARS-CoV-2 viral infection results in mild flu-like symptoms …

After emerging in China in late 2019, the novel coronavirus severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) spread worldwide, and as of mid-2021, it remains a …

Although the number of cases and mortality of COVID-19 are seemingly declining, clinicians
endeavor to establish indicators and predictors of such responses in order to optimize …

The rapid pace of the COVID-19 pandemic precluded traditional approaches to evaluating
clinical research and guidelines. We highlight notable successes and pitfalls of clinicians' …

Purpose To assess the prevalence of post-COVID symptoms in patients with recovered
COVID-19 (nasopharyngeal RT PCR negative) who were discharged from an acute COVID …

ABSTRACT BACKGROUND Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody)
may attenuate the inflammatory response in Covid-19. METHODS We performed an …

Abstract Background Hospitals in the Middle East Gulf region have experienced an influx of
COVID-19 patients to their medical wards and intensive care units. The hypercoagulability of …